Isolated oligonucleotides containing modified nucleotides
Described and featured herein are isolated oligonucleotides containing, from 5′ to 3′, a nicking enzyme recognition sequence, at least 9 nucleotides that specifically bind a target nucleic acid molecule, and 2′ modified nucleotides. The isolated oligonucleotides may be used in compositions and methods for quantifying detection of a target oligonucleotide in a sample in real time. These methods are compatible with target oligonucleotides amplified using a Nicking and Extension Amplification Reaction (NEAR) reaction.
1. An isolated oligonucleotide comprising from 5′ to 3′,
i) a first region comprising a nicking enzyme recognition sequence, and
ii) a second region comprising at least 9 nucleotides that specifically bind a complementary sequence on a target nucleic acid molecule;
wherein the second region comprises one or more 2′ modified nucleotides.
2. The isolated oligonucleotide of claim 1 , wherein the 2′ modification is selected from the group consisting of 2′-O-methyl, 2′-methoxyethoxy, 2′-fluoro, 2′-hydroxyl, 2′-allyl, 2′-O-[2-(methylamino)-2-oxoethyl], 4′-CH 2 —O-2′-bridge, 4′-(CH 2 ) 2 —O-2′-bridge, 2′-LNA, and 2′-O—(N-methylcarbamate) and base analogs.
3. The isolated oligonucleotide of claim 1 , wherein the one or more 2′ modified nucleotides are positioned at the 3′ terminus of the sequence complementary to the target nucleic acid molecule.
4. The isolated oligonucleotide of claim 1 , wherein the one or more 2′ modified nucleotides positioned in the sequence complementary to the target nucleic acid molecule are separated from the nick site by 1, 2, 3, 4, 5 or more unmodified nucleotides.
5. The isolated oligonucleotide of claim 1 , wherein the second region comprises 2 or more contiguous 2′ modified nucleotides.
6. The isolated oligonucleotide of claim 1 , wherein the nicking enzyme recognition sequence is 5′-GAGT-3′.
7. The isolated oligonucleotide of claim 1 , wherein at least one of the 2′ modifications is 2′-O-methyl.
8. The isolated oligonucleotide of claim 5 , wherein the second region comprises 5 or more contiguous 2′ modified nucleotides.